Shandong Lukang Pharmaceutical Co., Ltd. Class A

Shandong Lukang Pharmaceutical Co., Ltd. Class A

SSSE:600789
6.80
CNY
-0.05
(-0.73%)
0.13EPS
60.48P/E
8.20BMarket Cap
Shandong Lukang Pharmaceutical Co., Ltd. Class A
SSE:600789
(Shanghai Stock Exchange)

Recent

price

6.80

P/E

ratio

60.48

div

yld

1.50%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
2.87
3.59
3.09
3.13
3.12
2.35
3.31
3.5
3.92
4.31
4.8
5.53
6.52
6.99
6.95
6.16
5.47
Revenue per Share
0.17
0.02
-0.18
0.02
-0.17
0.01
0.04
0.15
0.19
0.14
0.26
0.1
0.16
0.28
0.44
0.12
0.13
Basic EPS, GAAP
0.02
-0.47
-0.22
0.04
-0.01
-0.08
-0.1
-0.68
-0.59
-0.54
-0.53
-0.35
0.02
0.3
0.14
0.38
- -
Free Cash Flow per Basic Share
0.04
0.08
0.12
0.11
0.1
0.06
0.07
0.09
0.13
0.14
0.13
0.19
0.16
0.16
0.26
0.18
0.1
Dividend per Share
2.18
2.2
2.01
2.02
1.86
2.39
2.45
2.59
3.32
3.43
3.65
3.73
3.79
4.03
4.36
4.89
5
Book Value per Share
2.1
2.05
1.73
1.71
1.56
2.11
2.17
2.26
3
2.82
3
2.89
2.94
3.1
3.37
4.02
4.1
Tangible Book Value per Share
766
651
756
706
740
1,027
757
743
849
866
876
891
863
879
897
936
1,050
Basic Weighted Avg Shares
2,196
2,333
2,339
2,211
2,312
2,410
2,506
2,599
3,330
3,733
4,205
4,924
5,621
6,147
6,233
5,766
5,745
Sales/Revenue/Turnover
8.22
2.07
-1.68
-2.14
-0.93
2.54
3.3
7.93
8.69
5.94
3.79
4.93
5.21
6.39
6.81
4.76
4.69
Operating Margin (%)
164
163
171
199
187
168
156
138
158
187
244
307
348
381
402
449
- -
Depreciation Expense
130
15
-134
11
-125
8
29
114
161
121
228
89
138
246
395
112
136
Net Income, GAAP
11.13
30.42
- -
49.45
- -
55.53
18.35
7.88
9.82
13.46
10.94
20.86
4.65
5.93
5.89
30.58
14.2
Effective Tax Rate (%)
5.9
0.64
-5.72
0.49
-5.42
0.33
1.16
4.39
4.85
3.25
5.42
1.81
2.46
4
6.33
1.95
2.37
Profit Margin (%)
173
29
-13
113
-44
309
224
465
658
-616
-619
-727
-620
130
1,069
1,553
1,915
Working Capital
31
23
375
518
303
163
303
930
742
98
551
693
867
1,309
1,686
1,089
1,326
LT Debt
1,677
1,694
1,607
1,635
1,504
1,905
1,982
2,099
3,070
3,172
3,359
3,428
3,507
3,741
4,062
5,257
5,375
Total Equity
5.7
-0.42
- -
-2.2
- -
0.13
0.79
3.79
4.2
2.44
4.63
1.62
2.34
4.05
6.24
1.5
1.85
Return on Invested Capital (%)
7
1.75
- -
2.06
- -
1.29
2.18
4.11
4.51
3.32
5.27
2.39
3.63
4.78
6.68
2.08
2.46
Return on Capital (%)
8.17
0.91
-8.41
0.71
-8.53
0.49
1.59
5.99
6.61
4.08
7.31
2.74
4.16
7.07
10.48
2.49
2.97
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
1,510
1,133
722
LT Borrowings
1,138
1,192
1,326
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,045
1,045
1,045
Market Capitalization
8,675
7,118
8,205

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
4,827
4,789
4,577
Cash, Cash Equivalents & STI
2,110
1,880
1,409
Accounts Receivable, Net
961
961
907
Inventories
1,249
1,311
1,445
Total Current Liabilities
3,148
2,971
2,662
Payables & Accruals
- -
- -
- -
ST Debt
1,510
1,133
722
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.44%
9.8%
29.42%
Free Cash Flow
211.09%
311.94%
190.62%
Net Income, GAAP
72.65%
12.23%
-71.54%
Sales/Revenue/Turnover
9.51%
6.9%
-7.49%
Total Cash Common Dividend
14.65%
12.39%
-28.78%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,799
1,481
1,387
1,566
6,233
2025
1,674
1,480
- -
1,142
5,766
2026
1,616
1,621
1,365
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.08
0.26
0.05
0.05
0.44
2025
0.09
0.03
- -
-0.03
0.12
2026
0.05
0.08
0.03
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.1
0.05
0.09
0.26
2025
0.02
0.11
- -
0.01
0.18
2026
0.01
0.01
0.06
- -
- -
Business
Shandong Lukang Pharmaceutical Co., Ltd. (600789.SS) is a China-based pharmaceutical company engaged in the research, development, manufacture, and sale of pharmaceutical products and intermediates. The company produces a range of active pharmaceutical ingredients (APIs) and finished dosage forms, including penicillin antibiotics such as amoxicillin, ampicillin, and 6-APA; cephalosporin antibiotics like cefazolin, cefotaxime, and cefuroxime; cardiovascular drugs; anti-infectives; and biochemical products, offered under its own brands and through contract manufacturing services. It operates primarily in the pharmaceutical industry, serving domestic hospitals, distributors, and international markets in Asia, Europe, and North America, with manufacturing facilities concentrated in Shandong province. Founded in 1966 and headquartered in Rizhao, Shandong province, the company maintains subsidiaries focused on API production, formulation drugs, and pharmaceutical intermediates, with no disclosed parent company. Shandong Lukang Pharmaceutical expanded its operations through strategic investments in production capacity and quality compliance to meet global standards such as GMP and FDA requirements. No major acquisitions, funding rounds, partnerships, new product launches, or reorganizations have been publicly reported in the last 1-2 years as of December 2025.